Analysts See $-0.14 EPS for Sorrento Therapeutics, Inc. (SRNE)

March 14, 2018 - By Marie Mckinney

 Analysts See $ 0.14 EPS for Sorrento Therapeutics, Inc. (SRNE)
Investors sentiment decreased to 0.67 in 2017 Q3. Its down 0.11, from 0.78 in 2017Q2. It dived, as 9 investors sold Sorrento Therapeutics, Inc. shares while 12 reduced holdings. 3 funds opened positions while 11 raised stakes. 8.31 million shares or 22.78% less from 10.76 million shares in 2017Q2 were reported.
Deutsche Bankshares Ag owns 357,941 shares. Geode Mgmt Ltd Liability has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Gagnon Secs Limited Co has invested 0.02% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Virtu Fin Limited Company owns 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 43,348 shares. Barclays Public Limited Company reported 30,700 shares. Fincl Bank Of Mellon invested in 0% or 33,534 shares. California Public Employees Retirement stated it has 36,800 shares. Crow Point Limited Liability Company holds 44,565 shares or 0.01% of its portfolio. Northern Trust holds 0% or 174,327 shares in its portfolio. Tower Rech Capital Ltd Liability Co (Trc) holds 2,872 shares. Financial Bank Of America Corp De stated it has 144,424 shares. Goldman Sachs Group Incorporated has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Dimensional Fund Advsrs Lp invested 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Art Advsrs Ltd Liability Corp reported 0.01% stake. Wildcat Cap Ltd Liability Corporation stated it has 2.80M shares.

Since January 23, 2018, it had 2 insider purchases, and 4 sales for $11.11 million activity. Shares for $895,500 were bought by Ng George K on Wednesday, February 28. 684,288 Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares with value of $5.18 million were sold by Asia Pacific MedTech (BVI) Ltd. 64,600 shares were bought by Ji Henry, worth $642,770.

Analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $-0.14 EPS on March, 20.They anticipate $0.30 EPS change or 68.18 % from last quarter’s $-0.44 EPS. The stock decreased 1.63% or $0.125 during the last trading session, reaching $7.525. About 1.17M shares traded. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has declined 73.31% since March 14, 2017 and is downtrending. It has underperformed by 90.01% the S&P500.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Ratings Coverage

Among 9 analysts covering Sorrento Therapeutics (NASDAQ:SRNE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sorrento Therapeutics had 27 analyst reports since July 29, 2015 according to SRatingsIntel. As per Monday, October 3, the company rating was initiated by TH Capital. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has “Buy” rating given on Thursday, February 1 by H.C. Wainwright. The company was initiated on Tuesday, December 22 by FBR Capital. Oppenheimer maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Wednesday, November 15. Oppenheimer has “Buy” rating and $6.0 target. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) earned “Buy” rating by H.C. Wainwright on Monday, September 18. The firm earned “Buy” rating on Thursday, June 15 by H.C. Wainwright. On Wednesday, November 25 the stock rating was maintained by Brean Capital with “Buy”. The rating was reinitiated by Rodman & Renshaw on Monday, December 7 with “Buy”. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Tuesday, February 20. H.C. Wainwright has “Buy” rating and $35.0 target. On Tuesday, April 5 the stock rating was maintained by Rodman & Renshaw with “Buy”.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $622.27 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.

More notable recent Sorrento Therapeutics, Inc. (NASDAQ:SRNE) news were published by: which released: “Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver …” on March 05, 2018, also with their article: “Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non …” published on February 28, 2018, published: “Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th …” on March 08, 2018. More interesting news about Sorrento Therapeutics, Inc. (NASDAQ:SRNE) were released by: and their article: “Sorrento Therapeutics: Explicating The New Data Finding” published on March 06, 2018 as well as‘s news article titled: “Sorrento Therapeutics: Insider Buying Alert” with publication date: March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: